The United Laboratories International Holdings Limited

中/EN
中文繁體 English
  • Investor Relations
    IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
  • Corporate
Investor Relations
  • IR Home
  • Corporate Overview
  • Financial Highlights
  • Financial Reports
  • ESG Reports
  • Regulatory Filings
  • Press Releases
  • Company
    Presentations
  • Stock Quotes &
    Charts
  • Analyst Coverage
  • FAQs
  • IR Contact

Latest News

MAR
31
CLARIFICATION ANNOUNCEMENT TO 2025 ANNUAL RESULTS ANNOUNCEMENT
MAR
26
Final dividend for the year ended 31 December 2025
MAR
25
Triple Agonist UBT251 Showed a Mean HbA1c Reduction of Up to 2.16% after 24 Weeks in Phase 2 Trial in Chinese Patients with Type 2 Diabetes

2025

Interim Report
PDF

ESG Report 2024

  • Environment
  • Social
  • Governance

Presentation

Investor Information

  • Regulatory Filings
  • Corporate Governance
  • Stock Quotes & Charts
  • FAQs

IR Contact

6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong
tulir@tul.com.hk
Disclaimer | Sitemap

Copyright © 2026 The United Laboratories International Holdings Limited. All rights reserved.